Biohoo Life Science Directory
|
|
Algeta AS
Algeta is focused on the development of alpha particle emitters as radiopharmaceuticals for the treatment of cancer. The Company is targeting metastatic and disseminated tumor types for which there is substantial unmet medical need. Its first product candidate Alpharadin is targeting skeletal bone metastases resulting from prostate and breast cancer. |
Norway
|
|
|
Cellectar Inc
Cellectar is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Our product candidates combine phospholipid ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. To date, Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. |
|
USA
|
|
|
Draximage Inc
We are a major supplier of lyophilized radiopharmaceutical kits for use with Technetium-99m including DRAXIMAGE® MAA, MDP, DTPA and Glucoheptonate. DRAXIMAGE® kits and radiopharmaceuticals are exported worldwide, with regulatory approval in USA, Canada, parts of Europe and South East Asia. With the introduction of it's Kit for the Preparation of Sodium Iodide I 131 Capsules and Solution USP, Therapeutic Oral in the USA in 2003, DRAXIMAGE has established itself as one of the leading suppliers of I 131 products in North America. DRAXIMAGE’s vision is to be a global partner of choice in delivering innovative imaging and radiopharmaceutical solutions. |
|
Canada
|
|
|
MAP Medical Technologies OY
MAP Medical Technologies Oy, founded in 1991, is an independent Finnish company. The mission of our company is to develop and manufacture radiopharmaceuticals to serve nuclear medicine professionals. Our highly devoted team and modern production facilities offer a unique setting for production of best quality pharmaceuticals. |
|
Finland
|
|
|
Oncura
Oncura is the acknowledged world leader in researching, developing and the commercialisation of Low Dose Rate (LDR) Brachytherapy. Oncura’s goal is to ensure that all cancer patients should have access to the minimally invasive benefits of brachytherapy when it is a suitable clinical option. |
|
USA
|
<<
Start <
Prev 1 2 Next >
End >>
